Skip to main content
Clinical Trials/NCT01868165
NCT01868165
Completed
Not Applicable

Assessing the Impact of Calcium Channel Blockers on COGnitive Function in the Very Elderly (AI-COG)

Imperial College London7 sites in 1 country337 target enrollmentJune 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cognitive Ability, General
Sponsor
Imperial College London
Enrollment
337
Locations
7
Primary Endpoint
Change in Cognitive Function as Measured Using the Extended Mini Mental State Exam
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

Older adults are at increased risk of high blood pressure and cognitive decline. High blood pressure itself also increases risk of cognitive decline. A particular type of blood pressure lowering drug (a calcium channel blocker(CCB)) may lower risk of dementia in younger adults but there is no clear evidence of it's impact in those >=80. It is important that we know whether CCB use impacts on cognitive function in this age group. This study will examine the impact of antihypertensives on change in cognitive function with a particular focus on CCBs.

Detailed Description

This study is an observational cohort study examining cognitive change in those participants taking antihypertensives and aged 80 and over and examining cognitive change in participants taking different types of antihypertensive medication.

Registry
clinicaltrials.gov
Start Date
June 2013
End Date
February 2016
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Aged 80 and over Receiving pharmacological treatment for hypertension Mini Mental State Exam score \>24 No other condition likely to limit life to less than one year or to prevent the taking of informed consent.

Exclusion Criteria

  • Aged under 80 years Not receiving pharmacological treatment for hypertension Mini Mental State Exam score \<25 Diagnosed with a condition likely to limit life to less than one year or to prevent the taking of informed consent.
  • Presence of a sensory impairment or an existing neuropsychological deficit of sufficient severity to prevent cognitive testing.
  • Presence of a condition that will prevent cognitive testing, registered blind, profoundly deaf, suffering from an aphasia.

Outcomes

Primary Outcomes

Change in Cognitive Function as Measured Using the Extended Mini Mental State Exam

Time Frame: 12 months

The change in cognitive function measured using the extended mini-mental state exam (this is an extended screening test which assesses several areas of cognitive function, the scale is from 0-100, higher scores are better, those without cognitive impairment would be expected to score close to maximum)

Study Sites (7)

Loading locations...

Similar Trials